Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94


The Δ133p53β isoform promotes an immunosuppressive environment leading to aggressive prostate cancer.

Kazantseva M, Mehta S, Eiholzer RA, Gimenez G, Bowie S, Campbell H, Reily-Bell AL, Roth I, Ray S, Drummond CJ, Reid G, Joruiz SM, Wiles A, Morrin HR, Reader KL, Hung NA, Baird MA, Slatter TL, Braithwaite AW.

Cell Death Dis. 2019 Aug 20;10(9):631. doi: 10.1038/s41419-019-1861-1.


CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan.

Vennin C, Mélénec P, Rouet R, Nobis M, Cazet AS, Murphy KJ, Herrmann D, Reed DA, Lucas MC, Warren SC, Elgundi Z, Pinese M, Kalna G, Roden D, Samuel M, Zaratzian A, Grey ST, Da Silva A, Leung W; Australian Pancreatic Genome Initiative (APGI), Mathivanan S, Wang Y, Braithwaite AW, Christ D, Benda A, Parkin A, Phillips PA, Whitelock JM, Gill AJ, Sansom OJ, Croucher DR, Parker BL, Pajic M, Morton JP, Cox TR, Timpson P.

Nat Commun. 2019 Aug 12;10(1):3637. doi: 10.1038/s41467-019-10968-6.


Regulation of the interferon-gamma (IFN-γ) pathway by p63 and Δ133p53 isoform in different breast cancer subtypes.

Mehta SY, Morten BC, Antony J, Henderson L, Lasham A, Campbell H, Cunliffe H, Horsfield JA, Reddel RR, Avery-Kiejda KA, Print CG, Braithwaite AW.

Oncotarget. 2018 Jun 26;9(49):29146-29161. doi: 10.18632/oncotarget.25635. eCollection 2018 Jun 26.


A mouse model of the Δ133p53 isoform: roles in cancer progression and inflammation.

Kazantseva M, Mehta S, Eiholzer RA, Hung N, Wiles A, Slatter TL, Braithwaite AW.

Mamm Genome. 2018 Dec;29(11-12):831-842. doi: 10.1007/s00335-018-9758-3. Epub 2018 Jul 10. Review.


Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development.

Kazantseva M, Eiholzer RA, Mehta S, Taha A, Bowie S, Roth I, Zhou J, Joruiz SM, Royds JA, Hung NA, Slatter TL, Braithwaite AW.

J Pathol. 2018 Sep;246(1):77-88. doi: 10.1002/path.5111. Epub 2018 Jul 31.


∆133p53 isoform promotes tumour invasion and metastasis via interleukin-6 activation of JAK-STAT and RhoA-ROCK signalling.

Campbell H, Fleming N, Roth I, Mehta S, Wiles A, Williams G, Vennin C, Arsic N, Parkin A, Pajic M, Munro F, McNoe L, Black M, McCall J, Slatter TL, Timpson P, Reddel R, Roux P, Print C, Baird MA, Braithwaite AW.

Nat Commun. 2018 Jan 17;9(1):254. doi: 10.1038/s41467-017-02408-0.


Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression.

Kazantseva M, Hung NA, Mehta S, Roth I, Eiholzer R, Rich AM, Seo B, Baird MA, Braithwaite AW, Slatter TL.

Sci Rep. 2017 May 8;7(1):1566. doi: 10.1038/s41598-017-01800-6.


Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12.

Slatter TL, Wilson M, Tang C, Campbell HG, Ward VK, Young VL, Van Ly D, Fleming NI, Braithwaite AW, Baird MA.

Oncoimmunology. 2015 Dec 17;5(3):e1112941. eCollection 2016 Mar.


A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.

Lasham A, Mehta SY, Fitzgerald SJ, Woolley AG, Hearn JI, Hurley DG, Ruza I, Algie M, Shelling AN, Braithwaite AW, Print CG.

Int J Cancer. 2016 Sep 1;139(5):1157-70. doi: 10.1002/ijc.30137. Epub 2016 May 26.


HDAC8 Inhibition Blocks SMC3 Deacetylation and Delays Cell Cycle Progression without Affecting Cohesin-dependent Transcription in MCF7 Cancer Cells.

Dasgupta T, Antony J, Braithwaite AW, Horsfield JA.

J Biol Chem. 2016 Jun 10;291(24):12761-70. doi: 10.1074/jbc.M115.704627. Epub 2016 Apr 12.


The Δ133p53 isoform and its mouse analogue Δ122p53 promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2.

Roth I, Campbell H, Rubio C, Vennin C, Wilson M, Wiles A, Williams G, Woolley A, Timpson P, Berridge MV, Fleming N, Baird M, Braithwaite AW.

Oncogene. 2016 Sep 22;35(38):4981-9. doi: 10.1038/onc.2016.45. Epub 2016 Mar 21.


Telomere length and periodontal attachment loss: a prospective cohort study.

Thomson WM, Zeng J, Broadbent JM, Foster Page LA, Shalev I, Moffitt TE, Caspi A, Williams SM, Braithwaite AW, Robertson SP, Poulton R.

J Clin Periodontol. 2016 Feb;43(2):121-7. doi: 10.1111/jcpe.12499. Epub 2016 Feb 19.


Δ122p53, a mouse model of Δ133p53α, enhances the tumor-suppressor activities of an attenuated p53 mutant.

Slatter TL, Hung N, Bowie S, Campbell H, Rubio C, Speidel D, Wilson M, Baird M, Royds JA, Braithwaite AW.

Cell Death Dis. 2015 Jun 11;6:e1783. doi: 10.1038/cddis.2015.149.


Alpha-enolase is upregulated on the cell surface and responds to plasminogen activation in mice expressing a ∆133p53α mimic.

Sawhney S, Hood K, Shaw A, Braithwaite AW, Stubbs R, Hung NA, Royds JA, Slatter TL.

PLoS One. 2015 Feb 2;10(2):e0116270. doi: 10.1371/journal.pone.0116270. eCollection 2015.


Increased paired box transcription factor 8 has a survival function in glioma.

Hung N, Chen YJ, Taha A, Olivecrona M, Boet R, Wiles A, Warr T, Shaw A, Eiholzer R, Baguley BC, Eccles MR, Braithwaite AW, Macfarlane M, Royds JA, Slatter T.

BMC Cancer. 2014 Mar 6;14:159. doi: 10.1186/1471-2407-14-159.


Internalizing disorders and leukocyte telomere erosion: a prospective study of depression, generalized anxiety disorder and post-traumatic stress disorder.

Shalev I, Moffitt TE, Braithwaite AW, Danese A, Fleming NI, Goldman-Mellor S, Harrington HL, Houts RM, Israel S, Poulton R, Robertson SP, Sugden K, Williams B, Caspi A.

Mol Psychiatry. 2014 Nov;19(11):1163-70. doi: 10.1038/mp.2013.183. Epub 2014 Jan 14.


Stimulating p53 down-under: a report from the 1st Australian p53 Workshop.

Neilsen PM, Braithwaite AW, Gamell C, Haupt S, Janic A, Strasser A, Wolyniec K, Haupt Y.

Cell Death Differ. 2013 Dec;20(12):1753-6. doi: 10.1038/cdd.2013.2. Epub 2013 Feb 1. No abstract available.


The mesenchymal architecture of the cranial mesoderm of mouse embryos is disrupted by the loss of Twist1 function.

Bildsoe H, Loebel DA, Jones VJ, Hor AC, Braithwaite AW, Chen YT, Behringer RR, Tam PP.

Dev Biol. 2013 Feb 15;374(2):295-307. doi: 10.1016/j.ydbio.2012.12.004. Epub 2012 Dec 19.


YB-1: oncoprotein, prognostic marker and therapeutic target?

Lasham A, Print CG, Woolley AG, Dunn SE, Braithwaite AW.

Biochem J. 2013 Jan 1;449(1):11-23. doi: 10.1042/BJ20121323. Review.


Enhanced isolation of fibroblasts from human skin explants.

Huschtscha LI, Napier CE, Noble JR, Bower K, Au AY, Campbell HG, Braithwaite AW, Reddel RR.

Biotechniques. 2012 Oct;53(4):239-44. doi: 10.2144/0000113939.


Activation of p53 following ionizing radiation, but not other stressors, is dependent on the proline-rich domain (PRD).

Campbell HG, Mehta R, Neumann AA, Rubio C, Baird M, Slatter TL, Braithwaite AW.

Oncogene. 2013 Feb 14;32(7):827-36. doi: 10.1038/onc.2012.102. Epub 2012 Apr 9.


Does Δ133p53 isoform trigger inflammation and autoimmunity?

Campbell HG, Slatter TL, Jeffs A, Mehta R, Rubio C, Baird M, Braithwaite AW.

Cell Cycle. 2012 Feb 1;11(3):446-50. doi: 10.4161/cc.11.3.19054. Epub 2012 Feb 1.


YB-1, the E2F pathway, and regulation of tumor cell growth.

Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL, Reid G, Woolley AG, Miller LD, Black MA, Shelling AN, Print CG, Braithwaite AW.

J Natl Cancer Inst. 2012 Jan 18;104(2):133-46. doi: 10.1093/jnci/djr512. Epub 2011 Dec 28.


The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival.

Royds JA, Al Nadaf S, Wiles AK, Chen YJ, Ahn A, Shaw A, Bowie S, Lam F, Baguley BC, Braithwaite AW, MacFarlane MR, Hung NA, Slatter TL.

PLoS One. 2011;6(10):e26737. doi: 10.1371/journal.pone.0026737. Epub 2011 Oct 26.


Dynamin inhibitors induce caspase-mediated apoptosis following cytokinesis failure in human cancer cells and this is blocked by Bcl-2 overexpression.

Joshi S, Braithwaite AW, Robinson PJ, Chircop M.

Mol Cancer. 2011 Jun 28;10:78. doi: 10.1186/1476-4598-10-78.


Prognostic association of YB-1 expression in breast cancers: a matter of antibody.

Woolley AG, Algie M, Samuel W, Harfoot R, Wiles A, Hung NA, Tan PH, Hains P, Valova VA, Huschtscha L, Royds JA, Perez D, Yoon HS, Cohen SB, Robinson PJ, Bay BH, Lasham A, Braithwaite AW.

PLoS One. 2011;6(6):e20603. doi: 10.1371/journal.pone.0020603. Epub 2011 Jun 10.


PAX8 promotes tumor cell growth by transcriptionally regulating E2F1 and stabilizing RB protein.

Li CG, Nyman JE, Braithwaite AW, Eccles MR.

Oncogene. 2011 Dec 1;30(48):4824-34. doi: 10.1038/onc.2011.190. Epub 2011 May 23.


Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform.

Slatter TL, Hung N, Campbell H, Rubio C, Mehta R, Renshaw P, Williams G, Wilson M, Engelmann A, Jeffs A, Royds JA, Baird MA, Braithwaite AW.

Blood. 2011 May 12;117(19):5166-77. doi: 10.1182/blood-2010-11-321851. Epub 2011 Mar 16.


The dynamin inhibitors MiTMAB and OcTMAB induce cytokinesis failure and inhibit cell proliferation in human cancer cells.

Joshi S, Perera S, Gilbert J, Smith CM, Mariana A, Gordon CP, Sakoff JA, McCluskey A, Robinson PJ, Braithwaite AW, Chircop M.

Mol Cancer Ther. 2010 Jul;9(7):1995-2006. doi: 10.1158/1535-7163.MCT-10-0161. Epub 2010 Jun 22.


Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing.

Cohen SB, Ma W, Valova VA, Algie M, Harfoot R, Woolley AG, Robinson PJ, Braithwaite AW.

Oncogene. 2010 Jan 21;29(3):403-10. doi: 10.1038/onc.2009.321. Epub 2009 Oct 19.


p53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors.

Slatter TL, Ganesan P, Holzhauer C, Mehta R, Rubio C, Williams G, Wilson M, Royds JA, Baird MA, Braithwaite AW.

Cell Death Differ. 2010 Mar;17(3):540-50. doi: 10.1038/cdd.2009.136. Epub 2009 Sep 25.


Normal human mammary epithelial cells proliferate rapidly in the presence of elevated levels of the tumor suppressors p53 and p21(WAF1/CIP1).

Huschtscha LI, Moore JD, Noble JR, Campbell HG, Royds JA, Braithwaite AW, Reddel RR.

J Cell Sci. 2009 Aug 15;122(Pt 16):2989-95. doi: 10.1242/jcs.044107. Epub 2009 Jul 28.


Increased apoptosis and reduced replication efficiency of the E3 region-modified dl309 adenovirus in cancer cells.

Hibma MH, Real NC, Wiles A, Dobson-Le D, Dix BR, Wynford-Thomas D, Braithwaite AW, Royds JA.

Virus Res. 2009 Oct;145(1):112-20. doi: 10.1016/j.virusres.2009.06.016. Epub 2009 Jul 2.


Accelerated decline in lung function in cigarette smokers is associated with TP53/MDM2 polymorphisms.

Hancox RJ, Poulton R, Welch D, Olova N, McLachlan CR, Greene JM, Sears MR, Caspi A, Moffitt TE, Robertson SP, Braithwaite AW.

Hum Genet. 2009 Oct;126(4):559-65. doi: 10.1007/s00439-009-0704-z. Epub 2009 Jun 12.


Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins.

Jiang WQ, Zhong ZH, Nguyen A, Henson JD, Toouli CD, Braithwaite AW, Reddel RR.

J Cell Biol. 2009 Jun 1;185(5):797-810. doi: 10.1083/jcb.200810084. Epub 2009 May 25.


PAX8 regulates telomerase reverse transcriptase and telomerase RNA component in glioma.

Chen YJ, Campbell HG, Wiles AK, Eccles MR, Reddel RR, Braithwaite AW, Royds JA.

Cancer Res. 2008 Jul 15;68(14):5724-32. doi: 10.1158/0008-5472.CAN-08-0058.


Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma.

Chen YJ, Hakin-Smith V, Teo M, Xinarianos GE, Jellinek DA, Carroll T, McDowell D, MacFarlane MR, Boet R, Baguley BC, Braithwaite AW, Reddel RR, Royds JA.

Cancer Res. 2006 Jul 1;66(13):6473-6.


p53: more research and more questions.

Braithwaite AW, Prives CL.

Cell Death Differ. 2006 Jun;13(6):877-80. No abstract available.


Some p53-binding proteins that can function as arbiters of life and death.

Braithwaite AW, Del Sal G, Lu X.

Cell Death Differ. 2006 Jun;13(6):984-93. Review.


p53 promotes adenoviral replication and increases late viral gene expression.

Royds JA, Hibma M, Dix BR, Hananeia L, Russell IA, Wiles A, Wynford-Thomas D, Braithwaite AW.

Oncogene. 2006 Mar 9;25(10):1509-20.


Y-box factor YB1 controls p53 apoptotic function.

Homer C, Knight DA, Hananeia L, Sheard P, Risk J, Lasham A, Royds JA, Braithwaite AW.

Oncogene. 2005 Dec 15;24(56):8314-25.


Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity.

He SJ, Stevens G, Braithwaite AW, Eccles MR.

Mol Cancer Ther. 2005 Jun;4(6):996-1003.


The p53 story: layers of complexity.

Braithwaite AW, Royds JA, Jackson P.

Carcinogenesis. 2005 Jul;26(7):1161-9. Epub 2005 Apr 7. Review.


Exploitation of cell cycle and cell death controls by adenoviruses: the road to a productive infection.

Russell IA, Royds JA, Braithwaite AW.

Prog Mol Subcell Biol. 2004;36:207-43. Review. No abstract available.


The deleted in colorectal carcinoma (DCC) gene 201 R --> G polymorphism: no evidence for genetic association with autoimmune disease.

Hall RJ, Merriman ME, Green RA, Markham VH, Smyth DJ, Heward JM, Jennings CE, Braithwaite AW, Cundy T, Darlow BA, Gow PJ, Harrison AA, Highton J, Hunt PJ, Manning P, Pokorny V, Scott RS, Taylor BJ, Willis JA, Yeoman S, McLean L, Gough SC, Pearce SH, Merriman TR.

Eur J Hum Genet. 2003 Nov;11(11):840-4.


The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions.

Edwards SJ, Hananeia L, Eccles MR, Zhang YF, Braithwaite AW.

Oncogene. 2003 Jul 17;22(29):4517-23.


The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor.

Lasham A, Moloney S, Hale T, Homer C, Zhang YF, Murison JG, Braithwaite AW, Watson J.

J Biol Chem. 2003 Sep 12;278(37):35516-23. Epub 2003 Jun 30.


Nuclear localization of Y-box factor YB1 requires wild-type p53.

Zhang YF, Homer C, Edwards SJ, Hananeia L, Lasham A, Royds J, Sheard P, Braithwaite AW.

Oncogene. 2003 May 8;22(18):2782-94.


Supplemental Content

Loading ...
Support Center